(DOTA(0)-Phe(1)-Tyr(3))octreotide (SMT 487)

02/15/2002 - "These studies showed that untreated animals and animals treated with no virus and 500 microCi [(90)Y]-SMT 487 had median tumor quadrupling times of 16 and 25 days, respectively. "
03/01/2015 - "Due to unspecific parenchymal binding and the expression of SSTRs on leukocytes in the spleen this is the organ with the highest non-tumor uptake of DOTATOC. "
08/01/2014 - "Weak signal in PET imaging, however, suggests only limited benefit of [(68)Ga]DOTATOC or [(18)F]FDR-NOC PET/CT in this tumor model for in vivo imaging of sstr2 status."
08/01/2014 - "The majority of subcutaneous tumors were not visualized by [(68)Ga]DOTATOC or [(18)F]FDR-NOC PET. "
08/01/2014 - "High tumor-to-muscle ratios were also observed in subcutaneous tumor-bearing mice after injection with [(68)Ga]DOTATOC and [(18)F]FDR-NOC with both autoradiography (6.7 ± 1.5 and 4.3 ± 0.8, respectively) and tissue radioactivity measurements (6.5 ± 0.8 and 4.8 ± 0.6, respectively). "

09/01/2012 - "Ga-DOTATOC PET/CT demonstrated an improved sensitivity in meningioma detection when compared to CE-MRI. "
03/01/2015 - "A very unusual and aggressive form of a primary pulmonary meningioma seen with a ⁶⁸Ga-DOTATOC PET/CT image."
02/01/2015 - "(68)Ga-DOTATOC-PET/MRI provided flawless image quality and presented an ideal combination of high sensitivity/specificity (PET) and the best possible morphological visualization of meningiomas (MRI). "
02/01/2015 - "Fifteen patients received (68)Ga-DOTATOC-PET/CT (0.5 h post injection [p.i.]) followed by PET/MRI 2 hours p.i. Both investigations were analyzed separately and then compared with respect to image quality, detection of intracranial meningiomas, and radiotracer uptake values (RUVs). "
02/01/2015 - "Comparison of ⁶⁸Ga-DOTATOC-PET/CT and PET/MRI hybrid systems in patients with cranial meningioma: Initial results."

10/01/2015 - "Time Evolution of DOTATOC Uptake in Neuroendocrine Tumors in View of a Possible Application of Radioguided Surgery with β- Decay."
07/01/2015 - "Positron emission tomography (PET)/computed tomography (CT) using (68)Ga-labeled 1,4,7,10-tetraazacyclododecane-N,N',N″,N‴-tetraacetic acid-D-Phe(1)-Tyr(3)-octreotide (DOTATOC) has been used to detect neuroendocrine tumors (NETs). "
06/01/2015 - "SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors."
05/01/2015 - "A 63-year-old man with a previously resected neuroendocrine tumor of the pancreas underwent Ga DOTATOC PET/CT, which showed intense Ga DOTATOC uptake in the left calvarium. "
01/01/2015 - "Monitoring Kidney Function in Neuroendocrine Tumor Patients Treated with (90)Y-DOTATOC: Associations with Risk Factors."

12/01/2008 - "Nevertheless, DOTATOC appears to be a treatment option for surgically incurable paragangliomas, because toxicity is very low and especially the fact that long lasting remissions could be achieved justifies the treatment. "
12/01/2008 - "We evaluated the effectiveness and toxicity of radiolabeled DOTATOC in patients with metastatic paraganglioma and pheochromocytoma. "
12/01/2008 - "Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma."
12/01/2008 - "In these 28 patients, it was shown that radiolabeled DOTATOC can be effective in patients with somatostatin receptor positive paraganglioma. "
10/01/2010 - "Seventeen subjects (age, 2-24 y) received at least 1 dose of (90)Y-DOTATOC; diagnoses included neuroblastoma, embryonal and astrocytic brain tumors, paraganglioma, multiple endocrine neoplasia IIB, and neuroendocrine tumors. "

10/01/2011 - "[Neuroendocrine pulmonary neoplasms: improved diagnosis by DOTATOC- vs. FDG-PET/CT]."